Caribou Biosciences, Inc.

CRBU · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders8.2%

Institutions44.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$11.16M	$9.99M	$34.48M	$13.85M	$9.60M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$148.34M	-$166.62M	-$116.06M	-$106.40M	-$66.98M
Operating income as a percentage of revenue.	-1329.4%	-1667.2%	-336.6%	-768.2%	-697.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$148.13M	-$149.10M	-$102.07M	-$99.42M	-$66.92M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.59	$-1.65	$-1.38	$-1.64	$-2.11
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.59	$-1.65	$-1.38	$-1.64	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$12.36M	$16.29M	$51.16M	$58.34M	$240.42M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$175.37M	$313.31M	$432.21M	$373.76M	$442.36M
Everything the company owes — debt, unpaid bills, and other obligations.	$53.19M	$60.36M	$63.81M	$72.89M	$54.53M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$122.17M	$252.95M	$368.40M	$300.87M	$387.82M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$111.00M	-$138.20M	-$93.30M	-$91.00M	-$32.50M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.36M	$4.88M	$11.61M	$6.45M	$2.12M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$112.36M	-$143.08M	-$104.91M	-$97.45M	-$34.62M

	You	Peer avg
Revenue Growth	-43.8%	-39.1%
ROE	-78.3%	-83.0%

Caribou Biosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison